Paul C. Hendrie

Hematology
825 Eastlake Ave E
Seattle, WA 98109

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms.

Journal: Leukemia
Published: January 16, 2026

Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia.

Diagnostic Yield of Repeat Blood Cultures and Risk Factors for Bloodstream Infection in Persistent Febrile Neutropenia.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 25, 2025

Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.

Predictors of Cardiac Recovery in Adults With AML Who Develop Heart Failure During Treatment.

Journal: JCO oncology practice
Published: April 03, 2025

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.

Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm.

Journal: Blood neoplasia
Published: October 22, 2024

Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.

Identification of factors predicting low-risk febrile neutropenia admissions in adults with acute myeloid leukemia.

Journal: Blood advances
Published: July 29, 2024

Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study.

Ceftriaxone-resistant viridans streptococci bacteraemia among patients treated at a large comprehensive cancer care centre: a retrospective eighteen-year study.

Journal: JAC-antimicrobial resistance
Published: January 19, 2024

Time independent factors that predict relapse in adults with acute myeloid leukemia.

Time independent factors that predict relapse in adults with acute myeloid leukemia.

Journal: Blood cancer journal
Published: November 10, 2023

Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.

Hyper-CVAD versus dose-adjusted EPOCH as initial treatment for adults with acute lymphoblastic leukemia.

Journal: European journal of haematology
Published: June 19, 2023

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.

Journal: Blood advances
Published: April 07, 2023

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Journal: Leukemia & lymphoma
Published: March 20, 2023

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

Journal: Leukemia & lymphoma
Published: March 10, 2023

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.

Journal: Leukemia & lymphoma
Published: March 09, 2023
Showing 1-12 of 61

Last Updated: 09/26/2026